Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last1,481 to 1,500 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Pre-Intervention vs Post-Intervention: Do Not Resuscitate Order | 2,282 of 3,243 2,127 of 2,823 | -5.0 points -7.2 to -2.7 | 6,066 | NCT00234286 Intervention to Improve Care at Life's End |
| Pre-Intervention vs Post-Intervention: Individuals With Pastoral Care Visit | 1,630 of 3,243 1,765 of 2,823 | -12.3 points -14.7 to -9.8 | 6,066 | NCT00234286 Intervention to Improve Care at Life's End |
| Pre-Intervention vs Post-Intervention: Sublingual Administration | 122 of 3,243 322 of 2,823 | -7.6 points -9.0 to -6.3 | 6,066 | NCT00234286 Intervention to Improve Care at Life's End |
| Pre-Intervention vs Post-Intervention: Presence of Order for Opioid Pain Medication | 2,004 of 3,243 2,056 of 2,823 | -11.0 points -13.4 to -8.7 | 6,066 | NCT00234286 Intervention to Improve Care at Life's End |
| Pre-Intervention vs Post-Intervention: Individuals Administered Antipsychotic Medication | 224 of 3,243 280 of 2,823 | -3.0 points -4.4 to -1.6 | 6,066 | NCT00234286 Intervention to Improve Care at Life's End |
| Lixisenatide vs Placebo: serious adverse events | 625 of 3,031 669 of 3,032 | -1.4 points -3.5 to 0.6 | 6,063 | NCT01147250 Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) |
| Cervarix Group vs Placebo Group: Number of Subjects With Serious Adverse Events (SAEs) | 56 of 3,026 81 of 3,025 | -0.8 points -1.6 to -0.1 | 6,051 | NCT00779766 Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects |
| Cervarix Group vs Placebo Group: Number of Subjects With Medically Significant Conditions (MSC) Regardless of Causal Relationship to Vaccination and Intensity | 186 of 3,026 185 of 3,025 | 0.0 points -1.2 to 1.2 | 6,051 | NCT00779766 Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects |
| Cervarix Group vs Placebo Group: deaths from any cause | 0 of 3,026 3 of 3,025 | -0.1 points -0.3 to 0.0 | 6,051 | NCT00779766 Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects |
| Cervarix Group vs Placebo Group: serious adverse events | 56 of 3,026 81 of 3,025 | -0.8 points -1.6 to -0.1 | 6,051 | NCT00779766 Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects |
| Linagliptin vs Glimepiride: deaths from any cause | 308 of 3,023 336 of 3,010 | -1.0 points -2.5 to 0.6 | 6,033 | NCT01243424 CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes |
| Linagliptin vs Glimepiride: serious adverse events | 1,403 of 3,023 1,448 of 3,010 | -1.7 points -4.2 to 0.8 | 6,033 | NCT01243424 CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes |
| Electronic AKI Alert vs Usual Care: Mortality | 272 of 3,059 265 of 2,971 | -0.0 points -1.5 to 1.4 | 6,030 | NCT02753751 Optimizing Electronic Alerts for Acute Kidney Injury |
| Electronic AKI Alert vs Usual Care: Number of Subjects With Chart Documentation of AKI | 2,141 of 3,059 1,871 of 2,971 | 7.0 points 4.6 to 9.4 | 6,030 | NCT02753751 Optimizing Electronic Alerts for Acute Kidney Injury |
| Electronic AKI Alert vs Usual Care: Dialysis | 106 of 3,059 93 of 2,971 | 0.3 points -0.6 to 1.2 | 6,030 | NCT02753751 Optimizing Electronic Alerts for Acute Kidney Injury |
| Electronic AKI Alert vs Usual Care: AKI Progression | 487 of 3,059 461 of 2,971 | 0.4 points -1.4 to 2.2 | 6,030 | NCT02753751 Optimizing Electronic Alerts for Acute Kidney Injury |
| Electronic AKI Alert vs Usual Care: deaths from any cause | 272 of 3,059 265 of 2,971 | -0.0 points -1.5 to 1.4 | 6,030 | NCT02753751 Optimizing Electronic Alerts for Acute Kidney Injury |
| Electronic AKI Alert vs Usual Care: Composite of Progression of AKI, Inpatient Dialysis, or Inpatient Death | 653 of 3,059 622 of 2,971 | 0.4 points -1.7 to 2.5 | 6,030 | NCT02753751 Optimizing Electronic Alerts for Acute Kidney Injury |
| HPV Self Testing vs HPV at Health Centers: Acceptability | 2,616 of 3,049 0 of 2,964 | 85.8 points 84.5 to 87.0 | 6,013 | NCT02095561 Evaluation of Human Papilloma Virus (HPV) Self-testing to Increase Screening Uptake |
| Finerenone (BAY94-8862) vs Placebo: First Occurrence of Renal Composite Events | 75 of 3,003 55 of 2,998 | 0.7 points -0.1 to 1.4 | 6,001 | NCT04435626 Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=75
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT00234286-7d9830a3",
"title": "Pre-Intervention vs Post-Intervention: Do Not Resuscitate Order",
"summary": "2282 of 3243 against 2127 of 2823; risk difference -5.0 points, 95% interval -7.2 to -2.7; NCT00234286, Intervention to Improve Care at Life's End",
"record": "/library/comparisons/NCT00234286-7d9830a3",
"nct_id": "NCT00234286",
"kind": "outcome",
"participants": 6066,
"risk_difference": {
"value": -0.04978433070755195,
"lower": -0.07205804302693433,
"upper": -0.027359539539710938
},
"group_1": "2,282 of 3,243",
"group_2": "2,127 of 2,823",
"difference": "-5.0 points",
"interval": "-7.2 to -2.7",
"trial_title": "Intervention to Improve Care at Life's End"
},
{
"id": "NCT00234286-c9eb75e8",
"title": "Pre-Intervention vs Post-Intervention: Individuals With Pastoral Care Visit",
"summary": "1630 of 3243 against 1765 of 2823; risk difference -12.3 points, 95% interval -14.7 to -9.8; NCT00234286, Intervention to Improve Care at Life's End",
"record": "/library/comparisons/NCT00234286-c9eb75e8",
"nct_id": "NCT00234286",
"kind": "outcome",
"participants": 6066,
"risk_difference": {
"value": -0.12260036576777966,
"lower": -0.14726389494180764,
"upper": -0.09769609019903666
},
"group_1": "1,630 of 3,243",
"group_2": "1,765 of 2,823",
"difference": "-12.3 points",
"interval": "-14.7 to -9.8",
"trial_title": "Intervention to Improve Care at Life's End"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=76",
"request_id": "Jmmd8oCyrILnJbHU"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant